Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2

Abstract The low proportion of gastric cancer (GC) patients with high HER2 expression limits the clinical application of trastuzumab, a humanized epidermal growth factor receptor 2 (HER2) antibody targeting for GC treatment. We found that Dicer was positively correlated with HER2 expression in GC ti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jianhua Wu, Qun Zhao, Yue Zhao, Xiaoyun Zhang, Yuan Tian, Zhanjun Guo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b3bcd3fb5f7b40a9b8fd47887dba0eb0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b3bcd3fb5f7b40a9b8fd47887dba0eb0
record_format	dspace
spelling	oai:doaj.org-article:b3bcd3fb5f7b40a9b8fd47887dba0eb02021-12-02T17:04:36ZDicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 210.1038/s41598-021-86485-82045-2322https://doaj.org/article/b3bcd3fb5f7b40a9b8fd47887dba0eb02021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86485-8https://doaj.org/toc/2045-2322Abstract The low proportion of gastric cancer (GC) patients with high HER2 expression limits the clinical application of trastuzumab, a humanized epidermal growth factor receptor 2 (HER2) antibody targeting for GC treatment. We found that Dicer was positively correlated with HER2 expression in GC tissue by immunostaining as well as induce HER2 overexpression without increasing invasiveness of GC cell. In addition, both the growth of GC referring to cell proliferation, invasion, migration and apoptosis was inhibited by Dicer overexpression. Moreover, the HER2 overexpression induced by Dicer provided more effective and additive target for trastuzumab to amplify the inhibition effect for GC cells in vitro and in vivo. Furthermore, as assessed in a subsequent experiment, calcitriol induced HER2 overexpression and amplified the inhibition effect of trastuzumab in GC cells referring to proliferation. Our finding demonstrated the calcitriol might increase indication of trastuzumab by inducing HER2 overexpression in GC patients. Dicer would be a potential target that extend the clinical indications of HER2 antibody in patients with low or negative HER2, who were not fit for HER2 antibody treatment before.Jianhua WuQun ZhaoYue ZhaoXiaoyun ZhangYuan TianZhanjun GuoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jianhua Wu Qun Zhao Yue Zhao Xiaoyun Zhang Yuan Tian Zhanjun Guo Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2
description	Abstract The low proportion of gastric cancer (GC) patients with high HER2 expression limits the clinical application of trastuzumab, a humanized epidermal growth factor receptor 2 (HER2) antibody targeting for GC treatment. We found that Dicer was positively correlated with HER2 expression in GC tissue by immunostaining as well as induce HER2 overexpression without increasing invasiveness of GC cell. In addition, both the growth of GC referring to cell proliferation, invasion, migration and apoptosis was inhibited by Dicer overexpression. Moreover, the HER2 overexpression induced by Dicer provided more effective and additive target for trastuzumab to amplify the inhibition effect for GC cells in vitro and in vivo. Furthermore, as assessed in a subsequent experiment, calcitriol induced HER2 overexpression and amplified the inhibition effect of trastuzumab in GC cells referring to proliferation. Our finding demonstrated the calcitriol might increase indication of trastuzumab by inducing HER2 overexpression in GC patients. Dicer would be a potential target that extend the clinical indications of HER2 antibody in patients with low or negative HER2, who were not fit for HER2 antibody treatment before.
format	article
author	Jianhua Wu Qun Zhao Yue Zhao Xiaoyun Zhang Yuan Tian Zhanjun Guo
author_facet	Jianhua Wu Qun Zhao Yue Zhao Xiaoyun Zhang Yuan Tian Zhanjun Guo
author_sort	Jianhua Wu
title	Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2
title_short	Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2
title_full	Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2
title_fullStr	Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2
title_full_unstemmed	Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2
title_sort	dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b3bcd3fb5f7b40a9b8fd47887dba0eb0
work_keys_str_mv	AT jianhuawu dicerincreasestheindicationfortrastuzumabtreatmentingastriccancerpatientsviaoverexpressionofhumanepidermalgrowthfactorreceptor2 AT qunzhao dicerincreasestheindicationfortrastuzumabtreatmentingastriccancerpatientsviaoverexpressionofhumanepidermalgrowthfactorreceptor2 AT yuezhao dicerincreasestheindicationfortrastuzumabtreatmentingastriccancerpatientsviaoverexpressionofhumanepidermalgrowthfactorreceptor2 AT xiaoyunzhang dicerincreasestheindicationfortrastuzumabtreatmentingastriccancerpatientsviaoverexpressionofhumanepidermalgrowthfactorreceptor2 AT yuantian dicerincreasestheindicationfortrastuzumabtreatmentingastriccancerpatientsviaoverexpressionofhumanepidermalgrowthfactorreceptor2 AT zhanjunguo dicerincreasestheindicationfortrastuzumabtreatmentingastriccancerpatientsviaoverexpressionofhumanepidermalgrowthfactorreceptor2
_version_	1718381869557350400

Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2

Ejemplares similares